Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Conditions
Major Depressive Disorder
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Neurocrine Clinical Site, Huntsville, Alabama, United States
Neurocrine Clinical Site, Bryant, Arkansas, United States
Neurocrine Clinical Site, Little Rock, Arkansas, United States
Neurocrine Clinical Site, Glendale, California, United States
Neurocrine Clinical Site, Los Angeles, California, United States
Neurocrine Clinical Site, Oceanside, California, United States
Neurocrine Clinical Site, Orange, California, United States
Neurocrine Clinical Site, Pico Rivera, California, United States
Neurocrine Clinical Site, San Diego, California, United States
Neurocrine Clinical Site, San Francisco, California, United States
Neurocrine Clinical Site, Upland, California, United States
Neurocrine Clinical Site, Cromwell, Connecticut, United States
Neurocrine Clinical Site, Farmington, Connecticut, United States
Neurocrine Clinical Site, Hollywood, Florida, United States
Neurocrine Clinical Site, Maitland, Florida, United States
Neurocrine Clinical Site, Maitland, Florida, United States
Neurocrine Clinical Site, Miami, Florida, United States
Neurocrine Clinical Site, Miami Gardens, Florida, United States
Neurocrine Clinical Site, Orlando, Florida, United States
Neurocrine Clinical Site, Palm Bay, Florida, United States
Neurocrine Clinical Site, Tampa, Florida, United States
Neurocrine Clinical Site, Tampa, Florida, United States
Neurocrine Clinical Site, Atlanta, Georgia, United States
Neurocrine Clinical Site, Gaithersburg, Maryland, United States
Neurocrine Clinical Site, Boston, Massachusetts, United States
Neurocrine Clinical Site, Watertown, Massachusetts, United States
Neurocrine Clinical Site, O'Fallon, Missouri, United States
Neurocrine Clinical Site, Saint Charles, Missouri, United States
Neurocrine Clinical Site, Cedarhurst, New York, United States
Neurocrine Clinical Site, Mount Kisco, New York, United States
Neurocrine Clinical Site, New York, New York, United States
Neurocrine Clinical Site, New York, New York, United States
Neurocrine Clinical Site, The Bronx, New York, United States
Neurocrine Clinical Site, Avon Lake, Ohio, United States
Neurocrine Clinical Site, Edmond, Oklahoma, United States
Neurocrine Clinical Site, Oklahoma City, Oklahoma, United States
Neurocrine Clinical Site, Philadelphia, Pennsylvania, United States
Neurocrine Clinical Site, Bellaire, Texas, United States
Neurocrine Clinical Site, Dallas, Texas, United States
Neurocrine Clinical Site, Houston, Texas, United States
Neurocrine Clinical Site, Richmond, Texas, United States
Neurocrine Clinical Site, Stafford, Texas, United States
Neurocrine Clinical Site, The Woodlands, Texas, United States
Neurocrine Clinical Site, Everett, Washington, United States
Neurocrine Clinical Site, Alken, Belgium
Neurocrine Clinical Site, Mechelen, Belgium
Neurocrine Clinical Site, Kardzhali, Bulgaria
Neurocrine Clinical Site, Plovdiv, Bulgaria
Neurocrine Clinical Site, Sofia, Bulgaria
Neurocrine Clinical Site, Sofia, Bulgaria
Neurocrine Clinical Site, Sofia, Bulgaria
Neurocrine Clinical Site, Sofia, Bulgaria
Neurocrine Clinical Site, Varna, Bulgaria
Neurocrine Clinical Site, Zagreb, Croatia
Neurocrine Clinical Site, Zagreb, Croatia
Neurocrine Clinical Site, Pilsen, Czechia
Neurocrine Clinical Site, Prague, Czechia
Neurocrine Clinical Site, Prague, Czechia
Neurocrine Clinical Site, Prague, Czechia
Neurocrine Clinical Site, Prague, Czechia
Neurocrine Clinical Site, Tallinn, Estonia
Neurocrine Clinical Site, Kuopio, Finland
Neurocrine Clinical Site, Oulu, Finland
Neurocrine Clinical Site, Tampere, Finland
Neurocrine Clinical Site, Budapest, Hungary
Neurocrine Clinical Site, Jelgava, Lativa, Latvia
Neurocrine Clinical Site, Liepāja, Lativa, Latvia
Neurocrine, Sigulda, Lativa, Latvia
Neurocrine Clinical Site, Jelgava, Latvia
Neurocrine Clinical Site, Liepāja, Latvia
Neurocrine Clinical Site, Kaunas, Lithuania
Neurocrine Clinical Site, Amsterdam, Netherlands
Neurocrine Clinical Site, Groningen, Netherlands
Neurocrine Clinical Site, Leiden, Netherlands
Neurocrine Clinical Site, Bełchatów, Poland
Neurocrine Clinical Site, Bialystok, Poland
Neurocrine Clinical Site, Bialystok, Poland
Neurocrine Clinical Site, Bialystok, Poland
Neurocrine Clinical Site, Bydgoszcz, Poland
Neurocrine Clinical Site, Gdansk, Poland
Neurocrine Clinical Site, Gdansk, Poland
Neurocrine Clinical Site, Grudziądz, Poland
Neurocrine Clinical Site, Katowice, Poland
Neurocrine Clinical Site, Craiova, Romania
Neurocrine Clinical Site, Bojnice, Slovakia
Neurocrine Clinical Site, Bratislava, Slovakia
Neurocrine Clinical Site, Košice, Slovakia
Neurocrine Clinical Site, Rimavská Sobota, Slovakia
Neurocrine Clinical Site, Svidník, Slovakia
Neurocrine Clinical Site, Vranov nad Topľou, Slovakia
Neurocrine Clinical Site, Gothenburg, Sweden
Neurocrine Clinical Site, Lund, Sweden
Neurocrine Clinical Site, Stockholm, Sweden
Neurocrine Clinical Site, Taipei, Taiwan
Neurocrine Clinical Site, Southampton, Hampshire, United Kingdom
Neurocrine Clinical Site, Sheffield, South Yorkshire, United Kingdom
Neurocrine Clinical Site, London, United Kingdom
Neurocrine Clinical Site, Manchester, United Kingdom
Study leads
Clinical Development Lead
Study Director
Neurocrine Biosciences